Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Juvenile Idiopathic Arthritis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Juvenile Idiopathic Arthritis. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Juvenile Idiopathic Arthritis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Research is led by Université Catholique de Louvain (1), Children's National Research Institute (1), Novartis Pharmaceuticals (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is No Intervention (other, 1 trial), followed by Secukinumab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Juvenile Idiopathic Arthritis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07000916

Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or...

Sponsor: Université Catholique de LouvainEnrolling: 10001 location
RECRUITINGNCT04833465

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable...

Sponsor: Children's National Research InstituteEnrolling: 901 location
RECRUITINGNCT07243782

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With...

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

Sponsor: Novartis PharmaceuticalsEnrolling: 761 location

Frequently Asked Questions

There are currently 3 clinical trials for Juvenile Idiopathic Arthritis, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Juvenile Idiopathic Arthritis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Juvenile Idiopathic Arthritis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.